Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
08/03/2020 08/04/2020 08/05/2020 08/06/2020 08/07/2020 Date
23.1(c) 22.61(c) 22.93(c) 23.02(c) 23.2(c) Last
582 183 614 037 456 817 449 171 277 812 Volume
+3.03% -2.12% +1.42% +0.39% +0.78% Change
More quotes
Financials
Sales 2020 462 M 544 M 544 M
Net income 2020 28,0 M 33,0 M 33,0 M
Net Debt 2020 177 M 209 M 209 M
P/E ratio 2020 125x
Yield 2020 -
Sales 2021 523 M 616 M 616 M
Net income 2021 47,9 M 56,5 M 56,5 M
Net Debt 2021 129 M 153 M 153 M
P/E ratio 2021 72,2x
Yield 2021 -
Capitalization 3 508 M 4 135 M 4 135 M
EV / Sales 2020 7,98x
EV / Sales 2021 6,96x
Nbr of Employees 3 030
Free-Float 89,9%
More Financials
Company
Evotec SE specializes in research and development services for the pharmaceutical and biotechnological industries. The group's activity is organized around 3 areas: - development of broadband screening systems; - research and development of pharmaceutical products: for the neurologic, oncologic, inflammatory diseases treatment; - other: target identification, pharmacological tests development, broadband screening... 
More about the company
Surperformance© ratings of Evotec SE
Trading Rating : Investor Rating :
More Ratings
Latest news on EVOTEC SE
08/05EVOTEC : to report first half-year 2020 results on 12 August 2020
PU
08/05EVOTEC : To report first half-year 2020 results on 12 august 2020
EQ
08/05EVOTEC : and Secarna Pharmaceuticals form strategic partnership in the field of ..
PU
08/05EVOTEC : And secarna pharmaceuticals form strategic partnership in the field of ..
EQ
07/31EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
07/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
07/30EVOTEC : Gets a Buy rating from Deutsche Bank
MD
07/24EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
07/22EVOTEC : Just - Evotec Biologics to produce monoclonal antibody products against..
PU
07/22EVOTEC : Just - evotec biologics to produce monoclonal antibody products against..
EQ
07/21EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
07/21EVOTEC : Gets a Buy rating from Baader Bank
MD
07/21EVOTEC : Enters partnership with quantro therapeutics
EQ
07/08EVOTEC : Initiates 'campus curie' in toulouse
EQ
07/01EVOTEC SE : Release according to Article 40, Section 1 of the WpHG [the German S..
EQ
More news
News in other languages on EVOTEC SE
08/07WOCHENVORSCHAU : Termine bis 21. August 2020
08/07WOCHENVORSCHAU : Termine bis 20. August 2020
08/05DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 05.08.2020 - 15.15 Uhr
08/05EVOTEC : to report first half-year 2020 results on 12 August 2020
08/05EVOTEC : To report first half-year 2020 results on 12 august 2020
More news
Analyst Recommendations on EVOTEC SE
More recommendations
Stock Trading Strategies
EVOTEC SE - 07/24
Back on price levels to sell
SELL
More Stock Trading Analysis
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 29,10 €
Last Close Price 23,20 €
Spread / Highest target 37,9%
Spread / Average Target 25,4%
Spread / Lowest Target 20,7%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE0.65%4 135
LONZA GROUP61.66%46 473
CELLTRION, INC.73.76%35 375
IQVIA HOLDINGS INC.3.90%30 707
MODERNA, INC.278.83%29 239
SEATTLE GENETICS, INC.40.43%27 918